Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2009

01-04-2009 | Short Communication

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer

Authors: Lorenzo Fornaro, G. Masi, S. Bursi, F. Loupakis, E. Vasile, A. Antonuzzo, S. Chiara, E. Pfanner, A. Di Paolo, G. Bocci, M. Del Tacca, A. Falcone

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2009

Login to get access

Abstract

Purpose

The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs.

Patients and methods

We treated 15 patients with escalating doses of capecitabine (from day 1 to 7) and fixed doses of oxaliplatin (85 mg/m2) plus irinotecan (165 mg/m2) (both administered on day 1), repeated every 2 weeks. Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment.

Results

The maximum tolerated dose of capecitabine resulted 2,000 mg/m2/day, with diarrhea being the only dose-limiting toxicity. Large interpatient variability in the pharmacokinetic parameters of investigated drugs was observed. Results in terms of activity are promising.

Conclusions

At the maximum tolerated dose of capecitabine of 2,000 mg/m2/day the combination is feasible with promising activity and deserves further investigations.
Literature
1.
Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214PubMedCrossRef
2.
Falcone A, Masi G, Allegrini G et al (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20:4006–4014PubMedCrossRef
3.
Masi G, Allegrini G, Cupini S et al (2004) First line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of phase II study with a simplified biweekly schedule. Ann Oncol 15:1766–1772PubMedCrossRef
4.
Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676PubMedCrossRef
5.
Twelves C, Xeloda Colorectal Cancer Group (2002) Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38:15–20PubMedCrossRef
6.
Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575PubMedCrossRef
7.
Scheithauer W, Kornek GV, Raderer M et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21:1307–1312PubMedCrossRef
8.
Ficarra R, Calabro ML, Cutroneo P et al (2002) Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J Pharm Biomed Anal 29:1097–1103PubMedCrossRef
9.
Falcone A, Di Paolo A, Masi G et al (2001) Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 19:3456–3462PubMed
10.
Di Paolo A, Danesi R, Ciofi L et al (2005) Improved analysis of 5-Fluorouracil and 5, 6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit 27:362–368PubMedCrossRef
11.
Koopman M, Antonini NF, Douma J et al (2007) Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–142PubMedCrossRef
12.
Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217–4223PubMedCrossRef
13.
Maroun J, Jonker DJ, Cripps C et al (2007) Capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC): phase I study findings. Proc Am Soc Clin Oncol (abstract 4086)
14.
Bajetta E, Celio L, Ferrario E et al (2007) Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 18:1810–1816PubMedCrossRef
15.
Rea DW, Nortier JW, Ten Bokkel Huinink WW et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16:1123–1132PubMedCrossRef
16.
Krishnamurthi SS, Brell JM, Hoppel CL et al (2008) Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol Apr 15 (Epub ahead of print)
Metadata
Title
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Authors
Lorenzo Fornaro
G. Masi
S. Bursi
F. Loupakis
E. Vasile
A. Antonuzzo
S. Chiara
E. Pfanner
A. Di Paolo
G. Bocci
M. Del Tacca
A. Falcone
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0840-5

Other articles of this Issue 5/2009

Cancer Chemotherapy and Pharmacology 5/2009 Go to the issue

Original Article

The Werner’s syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds

Original Article

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases

Original Article

Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer

Original Article

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

Original Article

Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine

Original Article

A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits